Fact Sheets

Selexis enables biopharmaceutical companies to produce virtually any recombinant therapeutic protein, because we have the ability to understand and modify our cells to address productivity and expression challenges.

SELEXIS Customer Survey Results Letter 2022

Posted by Selexis admin on Jun 16, 2022 11:48:00 AM
June 16, 2022

In 2022, Selexis surveyed our partners to collect feedback and gain insight about our company and technology. With our partners’ insights, we can build upon our business, continue to advance our technology and enhance our overall partner experience.

VIEW PDF